Wuhan Ammunition Life-tech Co., Ltd.

武汉艾米森生命科技股份有限公司

Develops methylation-based early cancer detection assays, including a qPCR liver cancer test and a non-invasive urine test for urothelial cancer, with four additional candidates in the pipeline.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Connected or related major customers / suppliers
• Distribution model
• Single product, business line or region
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Preferred shares and fair-value liabilities
• Non-recurring gains and losses
• Related-party transactions and balances
• Material share-based payments
• Chapter 18A biotech